Illumina Reports Mixed Financial Results Amid China Trade Tensions and Grail Divestiture Aftermath

News on February 7, 2025: Illumina, the gene sequencing giant, released a mixed earnings report while dealing with the impact of Chinese tariffs. This week, in response to the new tariff measures by the Trump administration, China placed Illumina on a government watchlist. Illumina stated that it would continue to operate in China as long as conditions permit, but it also has to face the challenge of declining annual revenue.

During the annual earnings call, Illumina CEO Jacob Thaysen told investors: "We recognize the significant opportunity within the Chinese market and are fully committed to navigating the current challenges with the hope of reaching a resolution as quickly as possible." He added that the company has reached out to China's Ministry of Commerce for more information.

From the specific financial data, Illumina's total revenue for the fiscal year 2024 was $4.3 billion, a 2% decrease compared to the previous fiscal year. However, its fourth-quarter sales performance was impressive, reaching $1.1 billion, representing a 1% increase compared to the same period in 2023. In terms of net profit, Illumina's core sequencing business achieved a full-year profit of $894 million. However, due to the divestiture of Grail last year, which resulted in impairment charges and other related expenses exceeding $1.88 billion, the company's final annual consolidated net loss reached $1.22 billion. Notably, as of the end of the fourth quarter last year, the company still held $1.22 billion in cash and cash equivalents.

Affected by this incident, Illumina's stock price plummeted this week, with a decrease of approximately 13%, bringing the per-share price down to about $111.66. On February 4, Illumina, along with PVH Corp, the apparel company owning brands such as Calvin Klein and Tommy Hilfiger, was added by the Chinese government to the "Unreliable Entity List."

In recent years, Illumina has actively expanded its market in China, opening its first manufacturing base in Shanghai in 2022. At that time, the company planned to start with the production of sequencing reagents and gradually expand into instruments and consumables by 2028. Looking ahead to 2025, Illumina stated that its financial forecast did not take into account the potential impacts of the latest developments in China or new tariff policies from the U.S. government, including the currently suspended 25% tariffs on Canada and Mexico, as well as possible measures these countries might adopt. The company expects core revenue to achieve low single-digit growth, with revenue ranging between approximately $4.28 billion and $4.4 billion.

The experience of Illumina this time fully reflects the complex impact of international trade policies on enterprises. The future development direction of Illumina in the Chinese market and the adjustment of its global business layout will undoubtedly be worth continuous attention.